Dr. Zou Ruiyang
Co-founder and CTO, MiRXES
Dr. Zou Ruiyang is Co-founder and CTO of MiRXES. Dr. Zou is responsible for MiRXES’s technology and diagnostic test developments, and also oversees operations in China. Prior to founding MiRXES, he was the Head of Bioinformatics at the miRNA Signature Identification Center, A*STAR. He has a passion for science and is continuously innovating to discover technology that can be developed to practical applications that can be delivered to the public. Dr. Zou has a PhD in Chemical and Pharmaceutical Engineering from Singapore-MIT Alliance (NUS-MIT), Singapore. He also successfully completed his dual degree in 2007 where he attained Bachelor of Science, Molecular Science and Engineering, Nankai University, Tianjin, China, and Bachelor of Engineering, Molecular Science and Engineering, Tianjin University, Tianjin, China. Dr. Zou has co-authored more than 10 publications and has 8 patents and applications.
MiRXES is a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered cancer early detection tests.
MiRXES’ story began in early 2000 when the founders pioneered a highly sensitive, specific and robust detection technology for MicroRNA (miRNA), the smallest genetic material ever found in human and other living organisms. Realizing the potential of miRNA-based clinical applications in solving unmet needs in cancer, cardiovascular, metabolic and infectious diseases, MiRXES decided to bring its technology from laboratory to clinic. In 2014, MiRXES spun off from A*STAR to commercialize the technology, develop accurate multi-cancer early detection solutions and make them readily available and accessible.
MiRXES believes that the future of health care will shift from treating the sick to preventive health care. The company’s focus on science and innovation will continue as it commits to changing lives and delivering preventive health care solutions to all.